SyntheMed plans 2006 launch for cardiac surgery adhesion barrier:
This article was originally published in Clinica
Executive Summary
SyntheMed, formerly Life Medical Sciences, says it has enrolled the first patient in a multicentre European trial testing its REPEL-CV adhesion barrier in cardiac surgery, in preparation for an anticipated 2006 EU product launch. The Oceanport, New Jersey firm is also testing the adhesion barrier in US trials designed to support a marketing application for the product. Post-operative adhesion formation can be a serious complication of open-heart surgery, the firm said, adding that REPEL-CV could become the first adhesion barrier approved by the FDA for use in cardiac surgery. The product targets an annual worldwide market opportunity estimated to be worth around $250m.